Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche. 

Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.

During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.

Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.